Trial Profile
A Phase I Safety and Bioimaging Trial of KB004 in Patients With Glioblastoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 Nov 2021
Price :
$35
*
At a glance
- Drugs Ifabotuzumab (Primary)
- Indications Glioblastoma
- Focus Adverse reactions
- 03 Nov 2021 Status changed from active, no longer recruiting to completed.
- 22 Oct 2021 According to a Humanigen media release, results will be presented at the Annual Congress of the European Association of Nuclear Medicine (EANM21).
- 29 Jun 2021 Planned End Date changed from 22 Apr 2021 to 22 Sep 2021.